Teva Pipeline Strengthens Growth Case as TD Cowen Initiates Coverage

 StocksRunner
 
  StocksRunner
 
Follow  Message
 
 
Find out what happening right now and get all the pieces of the puzzle on important data activity before the major news sources break the story and see what are the trends
 

•  01 Oct 2026
 

$TEVA Teva received a Buy rating from US investment house TD Cowen, which initiated coverage by highlighting the combination of a broad generic and biosimilar base with a growing innovative pipeline. The call adds to a series of positive developments for Teva in 2026, including its return to investment grade status and agreement with the Trump administration. The investment case is increasingly centered on earnings momentum, pipeline growth and a potential shift in how the market values the business.

TD Cowen views Teva as a global biopharma company with two operating engines: a broad generic and biosimilar portfolio generating stable cash flow, and an expanding innovative pipeline providing additional growth. Under CEO Richard Francis, Teva has shifted its strategy toward innovative medicines, led by Austedo for movement disorders, alongside Ajovy and Uzedy. The generic business remains the cash generating base that funds this transition, creating a combination of stability and growth that is attracting positive analyst coverage.

The TD Cowen initiation follows a strong year for the stock after a prolonged period defined by heavy debt and litigation. In 2026, S&P returned Teva to investment grade status, after which the company raised more than $1 billion of debt under more favorable conditions and reduced its financing burden. The improved credit profile strengthens the financial backdrop and supports the broader institutional flows around the stock.

Teva also strengthened its position on US regulation after becoming one of nine companies to sign an agreement with the Trump administration concerning drug prices. The agreement reduces part of the uncertainty surrounding the pharmaceutical sector. At the operating level, investors are focused on the companys pipeline, with Austedo remaining the primary growth engine and continuing to deliver rapid sales growth, while Uzedy, Ajovy and a long acting version of olanzapine remain important components of the growth strategy.

In biologic medicines, Teva is developing duvakitug, an antibody for inflammatory bowel diseases in partnership with Sanofi, while also advancing a biosimilar pipeline targeting opportunities created by patent expirations on expensive branded medicines. The combination of innovative medicines and biosimilars is central to the companys strategy. If pipeline growth continues while generic competition intensifies, the mix could support multiple expansion by changing the markets perception of Teva from a leveraged generic manufacturer toward a broader growth oriented biopharma company.

TD Cowen is not alone in its positive view. Oppenheimer recently raised its price target to $50 and maintained its positive view, arguing that innovative medicines can offset generic erosion, while S&P and Moody rating agency both returned Teva to investment grade status. Institutional investors have also increased exposure to the stock, reinforcing the shift in positioning around the company.

The operating backdrop has also improved. In its latest quarterly report, Teva beat expectations and raised its full year guidance, adding further earnings momentum to the stock. The shares have already risen sharply since the beginning of the year and have become one of the more prominent names in Tel Aviv and Wall Street, meaning the TD Cowen Buy initiation reinforces an existing trend rather than creating a new one.

The key positioning question is whether Teva can continue expanding its innovative pipeline while generic competition erodes the legacy business. The interaction between innovative medicine growth, biosimilar expansion, improved credit conditions, earnings momentum and institutional flows will determine whether the market continues to revalue Teva beyond its traditional generic drug profile.

View all market intelligence